Drug Biowaivers: Requirements, BCS, and Application in Chile and LATAM.
A drug biowaiver is a regulatory strategy that allows therapeutic equivalence to be demonstrated without conducting in vivo bioequivalence studies, reducing the time and costs associated with marketing authorization. In countries such as Chile, its application is based on the Biopharmaceutics Classification System (BCS) and specific regulatory criteria that pharmaceutical companies must carefully assess.
What is a drug biowaiver?
A drug biowaiver is a regulatory strategy that allows therapeutic equivalence to be demonstrated without the need to conduct in vivo bioequivalence studies, significantly reducing the time and costs associated with pharmaceutical development and marketing authorization.
Instead of clinical studies in humans, a biowaiver is supported by scientific evidence based on the Biopharmaceutics Classification System (BCS), together with in vitro studies and a comprehensive assessment of the formulation.
In markets such as Chile and other Latin American countries, this tool has become a key component for optimizing regulatory market access strategies.
How does the Biopharmaceutics Classification System (BCS) work?
The Biopharmaceutics Classification System (BCS) is a scientific model that classifies active pharmaceutical ingredients according to two fundamental parameters: aqueous solubility and intestinal permeability.
This approach is mainly applicable to immediate-release solid oral dosage forms and makes it possible to predict the behavior of the drug product in the body.
In addition, the BCS considers the product’s dissolution kinetics, the potential impact of excipients, and the relationship between dissolution and absorption.
BCS Classification: Classes I, II, III and IV
Class I: High solubility, high permeability
Class II: Low solubility, high permeability
Class III: High solubility, low permeability
Class IV: Low solubility, low permeability
From a regulatory perspective, Classes I and III are the most relevant for biowaivers.
Requirements for drug biowaivers in Chile
In Chile, biowaivers are regulated through technical guidelines issued by the Institute of Public Health of Chile (ISP).
Requirements include: BCS classification, dissolution studies, scientific justification, excipient assessment, and evidence of therapeutic equivalence.
The role of excipients in a biowaiver
Excipients may influence bioavailability. For Class III, qualitative sameness (Q1) and quantitative similarity (Q2) are required.
When is a biowaiver not applicable?
A biowaiver does not apply to narrow therapeutic index drugs, modified-release dosage forms, products intended for local action in the gastrointestinal tract, or Class II and IV active pharmaceutical ingredients.
Biowaiver based on dose proportionality
This approach allows bioequivalence to be extrapolated across different strengths when proportionality in the formulation can be demonstrated.
Advantages of biowaivers in LATAM regulatory strategies
Biowaivers reduce costs, accelerate marketing authorization processes, optimize lifecycle management, and facilitate market access.
Common mistakes in biowaiver applications
Common mistakes include assuming automatic eligibility, underestimating the impact of excipients, and failing to consider regulatory differences across jurisdictions.
Conclusion
A biowaiver is a strategic decision that makes it possible to optimize resources and accelerate market access. Reviewing Chilean regulations on biowaivers is highly useful for understanding this regulatory strategy.